William C. Roberts
Investor Relations Contact presso G1 THERAPEUTICS, INC.
Profilo
William C.
Roberts is currently the VP-Investor Relations & Corporate Communications at G1 Therapeutics, Inc. Prior to this, he held positions as Vice President-Communications & Investor Relations at Shire ViroPharma, Inc., Vice President-Investor Relations & Communications at Zynerba Pharmaceuticals, Inc., Head-Investor Relations at Medimmune, Inc., Vice President-Investor Relations at Adaptimmune Therapeutics Plc, and Vice President-Corporate Communications at Viropharma, Inc. Mr. Roberts received his undergraduate degree from the University of Virginia and his MBA from Keller Graduate School of Management.
Posizioni attive di William C. Roberts
| Società | Posizione | Inizio |
|---|---|---|
| G1 THERAPEUTICS, INC. | Investor Relations Contact | 04/01/2021 |
Precedenti posizioni note di William C. Roberts
| Società | Posizione | Fine |
|---|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Investor Relations Contact | 23/10/2017 |
| Viropharma, Inc. | Public Communications Contact | - |
| ZYNERBA PHARMACEUTICALS, INC. | Investor Relations Contact | - |
| Medimmune, Inc. | Investor Relations Contact | - |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Investor Relations Contact | - |
Formazione di William C. Roberts
| University of Virginia | Undergraduate Degree |
| Keller Graduate School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| ZYNERBA PHARMACEUTICALS, INC. | Health Technology |
| G1 THERAPEUTICS, INC. | Health Technology |
| ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
| Aziende private | 3 |
|---|---|
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
| Medimmune, Inc. | Health Technology |
| Viropharma, Inc. |
- Borsa valori
- Insiders
- William C. Roberts
